ACRE advice: application for a clinical, vaccine trial of genetically modified Bordetella pertussis (21/R53/01), (22/R53/01) and (26/R59/01)
ACRE's advice on an application for a clinical, vaccine trial of genetically modified Bordetella pertussis.
Documents
Details
These documents are the advice of the Advisory Committee on Releases to the Environment (ACRE) to government on 3 applications from ILiAD Biotechnologies, Inc and hVIVO Services Ltd to carry out clinical, vaccine trials of genetically modified Bordetella Pertussis.
The committee advised that the risks to human health and the environment from this trial are extremely low.